Study of IBI130 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests IBI130 in people with unresectable, locally advanced, or metastatic solid tumors (cancers that can’t be fully removed by surgery or have spread). It may help find whether the drug is safe and can work against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can understand the study and sign consent
- Your current activity level is fairly good (ECOG 0 or 1, meaning you’re able to do most daily tasks)
- You expect to live at least 12 weeks (based on your doctor’s estimate)
- Your blood counts and key organs (like liver and kidneys) are working well enough for treatment
- You can’t be in another experimental (interventional) drug study at the same time
- You haven’t had anti-cancer treatment recently (within 4 weeks or within 5 drug “half-lives,” whichever is shorter)
- You won’t take other anti-cancer treatments during the study except for symptom-relief radiation (palliative radiation), if approved
- You haven’t had a live vaccine in the last 4 weeks and don’t plan any live vaccines during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
This trial tests an experimental drug called IBI3005 for people whose solid tumors (cancers that form lumps) have continued to grow despite treatment with a specific targeted therapy (EGFR TKI). The goal is to see if IBI3005 can help when other treatments have stopped working.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.